Learning With Lowell
Learning With Lowell
Lowell Thompson
Episodes
About
Reviews
Promote
40: Computational Antibody Drug Discovery Platform with Machine Learning Startup, Antiverse, with the Co-Founder Murat Tunaboylu
31 minutes Posted Jun 26, 2018 at 4:19 pm.
] What is unique about what they are developing, Murat's background, and the amazing improvements they are working to create in decreasing drug discovery time
] His origin story of getting into biotech, and what drives him to work long hours to create something from nothing.
] The key skills that his co-founders bring to the team.
] How the machine learning works, and how difficult it is to understand.
] If the technology ever replaces humans and digitizes the entire process of drug development.
] How long from today it will take them to have the finished product that they are developing.
] Key people, skills, and resources they need to help develop Antiverse.
] How certain he is in what they are trying to develop coming into the world.
] What is unique about what they are developing that gives them a competitive edge.
0:00
31:56
Download MP3
Show notes
Machine Learning, Antibodies, and Drug discovery.
Antiverse is building a world-first computational antibody drug discovery platform. We combine in-house lab expertise with state of the art machine learning to predict antibody-antigen binding and provide antibody drug candidates in one day. Source
Click here for the quick text interview we had:
Quick Text Interview with Murat Co-Founder of Antiverse An AI Antibody Drug Discovery Platform
Website
Contact info: [email protected]
"Antiverse: Leveraging AI to Achieve Antibody Drug Discovery in One Day
BETTER MEDICINES FASTER
Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day.
A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen taget sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months." Source
The Team (see more on their website)
Murat Tunaboylu has a BSc in Electrical Engineering and twelve years of experience as a software engineer. He also has extensive experience in labware automation and will be automating the lab work and creating the software that customers will use. Linked in Profile
Rowina has a PhD in Biochemistry from the University of Cambridge in cell-free protein synthesis and will be using this cutting-edge technique for the high-throughput generation of antibody fragments. She previously worked as a protein synthesis scientist for drug development for the contract research organisation Domainex. Linkedin Profile 
Ben Holland has an MEng in Engineering Science from the University of Oxford and experience in mathematical modelling, especially neural networks, and will use the generated data to train the machine learning system. Linkedin Profile 
Hyperlinked Timestamped Show Notes
* [
* [
* [
* [
* [
* [
* [
* [
* [
This podcast uses Blubrry for stats, and dynamic audio. Learn more on this podcast's About tab. Dynamic Audio may cause this episode's timestamps to be slightly off.
← See all 237 episodes of Learning With Lowell
Podbay © 2026 Fancy Soups
About